Form 4: IOVANCE Officer's RSU Vesting and Tax-Related Share Sale

IOVANCE BIOTHERAPEUTICS' Chief Regulatory Officer, Raj K. Puri, reported the vesting of 5,470 restricted stock units and a subsequent sale of 2,798 shares to cover tax obligations.

Summary

• Raj K. Puri, Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS, INC. (IOVA), reported transactions on March 2, 2026.
• 5,470 restricted stock units (RSUs) vested, converting into common stock.
• 2,798 shares of common stock were withheld by the Issuer at a price of $3.79 per share to satisfy mandatory tax withholding requirements.
• This withholding was not an open market sale of securities.
• Following these transactions, Puri beneficially owns 218,531 shares of common stock.
• Puri also holds 21,878 remaining restricted stock units, which will vest in equal quarterly installments, originating from a grant on March 1, 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine and expected compensation event, reflecting the normal course of executive incentive plan execution rather than a significant operational or strategic development.

Positives

• The vesting of 5,470 restricted stock units indicates a successful milestone for the executive's compensation plan, aligning executive interests with shareholder value creation.

Negatives

• 2,798 shares were disposed of to cover tax liabilities, resulting in a reduction of the executive's direct common stock holdings.

Future Outlook

The remaining 21,878 restricted stock units held by Raj K. Puri are scheduled to vest in equal quarterly installments.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related share dispositions are standard practices for executive compensation in the biotechnology industry, reflecting the realization of long-term incentive awards and are routine events.

Comparison to Industry Standards

• The practice of withholding shares for tax purposes upon RSU vesting is a common industry standard across publicly traded companies, including those in the biotechnology sector like IOVANCE, and is consistent with compensation practices seen at peers such as Amgen Inc. or Gilead Sciences, Inc.
• The vesting schedule of RSUs, often tied to performance or time-based milestones, aligns with typical executive incentive structures designed to retain talent and align interests with shareholders over the long term.

Related Party Transactions

• The withholding of shares by the Issuer to satisfy tax obligations upon RSU vesting is a standard related-party transaction inherent in executive compensation plans.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine executive compensation event, reflecting the ongoing execution of incentive plans.
• Executive (Raj K. Puri): Realization of long-term incentive compensation, increasing personal wealth, offset by tax obligations.

Next Steps

• The remaining 21,878 RSUs will continue to vest in equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving RSU vesting and tax-related share withholding. It does not provide new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should consider this a standard disclosure.

Keywords

IOVANCE, IOVA, Form 4, insider transaction, RSU vesting, stock transaction, executive compensation, Raj K. Puri